Edible Roulette or a Sure Bet? Evaluating Testing Standards and Consistency in Colorado’s Edible Products (2024)
Cinnamon Bidwell, PhD,
Institute of Cognitive Science Faculty, Associate Professor, University of Colorado Boulder
Duncan Mackie, PhD,
Director of Pharmacology & Experimental Therapeutics, MedPharm Holdings
This groundbreaking research is shedding light on the accuracy of product labeling in Colorado.
In Colorado, all cannabis products must carry state-mandated labels detailing the potency […]
Identifying the neuronal cell-types responsible for the rewarding and aversive properties of THC (2023)
David Root, PhD
Assistant Professor, Department of Psychology and Neuroscience, University of Colorado Boulder
Marijuana is among the most widely used psychoactive substances across the world. The active ingredient in marijuana, Δ9-tetrahydrocannabinol (THC), has rewarding qualities and some individuals will become addicted to using it. THC has aversive properties as well at higher doses. On […]
Cannabinoids and Traumatic Brain Injury: A Randomized, Placebo Controlled Trial (2022)
Kent Hutchison, PhD
Institute of Cognitive Science Affiliated Faculty & Professor, University of Colorado Boulder
Traumatic brain injury (TBI) represents a major public health burden due to chronic neuropsychiatric sequelae (emotional, physical and cognitive) that negatively affect vocational activities, interpersonal relationships and independent living. Responses of these chronic symptoms to any particular treatment are both […]
Isolation and Pharmacological Evaluation of Phytocannabinoids for Alzheimer’s Disease (2022)
Cinnamon Bidwell, PhD,
Institute of Cognitive Science Faculty, Assistant Professor, University of Colorado Boulder
Duncan Mackie, PhD,
Director of Pharmacology & Experimental Therapeutics, MedPharm Holdings
Our research group has a longstanding interest in the activity of cannabinoids for the treatment of inflammatory neurological diseases such as Alzheimer’s disease. The purpose of this proposal is to […]
Preventative and treatment effects of broad-spectrum cannabidiol (CBD) in a rat model of comorbid autism and epilepsy: A mechanistic study (2022)
Christopher Lowry, PhD
Associate Professor, Integrative Physiology, University of Colorado Boulder
In groundbreaking research at the University of Colorado Boulder, Dr. Christopher Lowry, Associate Professor of Integrated Physiology, is investigating the biological connection between autism spectrum disorder and epilepsy using cannabidiol (CBD) as a potential preventative intervention.
“We became interested in this project because […]
Dissecting the Genetic Basis of Sex and Dioecy in Cannabis Sativa (2021)
Nolan Kane, PhD
Associate Professor, Ecology and Evolutionary Biology, University of Colorado Boulder
As hemp continues to become an ever more economically valuable/important crop, it becomes increasingly necessary to understand the mechanism of sex determination. Understanding these processes will help to develop new approaches, tools, and pipelines, which will propel Cannabis into the modern era as […]
Is What You See What You Get? A Systematic, Public Health-driven Analysis of Cannabis Product Label Claims VS. Actual Cannabinoid Content (2021)
Cinnamon Bidwell, PhD
Institute of Cognitive Science Faculty, Assistant Professor, University of Colorado Boulder
Duncan Mackie, PhD
Director of Pharmacology & Experimental Therapeutics, MedPharm Holdings
This project constitutes an independent and comprehensive evaluation of cannabis product label claims and testing infrastructure in the State of Colorado. The primary aim is to determine the actual cannabinoid potency (via […]